PE20050077A1 - Derivados de 4-pirrolidino-fenil-bencil-eter - Google Patents
Derivados de 4-pirrolidino-fenil-bencil-eterInfo
- Publication number
- PE20050077A1 PE20050077A1 PE2003000952A PE2003000952A PE20050077A1 PE 20050077 A1 PE20050077 A1 PE 20050077A1 PE 2003000952 A PE2003000952 A PE 2003000952A PE 2003000952 A PE2003000952 A PE 2003000952A PE 20050077 A1 PE20050077 A1 PE 20050077A1
- Authority
- PE
- Peru
- Prior art keywords
- phenyl
- halogen
- pyrrolidine
- benzyloxy
- oxo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
REFERIDA A UN COMPUESTO DE FORMULA I, DONDE X-Y ES -CH2-CH2-, -CH=CH-, -CH2-O-; R1, R1.1 Y R1.2 SON CADA UNO H, HALOGENO, CIANO, ENTRE OTROS; R21, R22 Y R23 SON CADA UNO H, HALOGENO; R24 ES H, HALOGENO, METILO; R3 ES H; R4 ES -CONHR5, -CN O -NHR6; R5 ES H, ALQUILO C1-C3; R6 ES -CO-H, -CO-NH2, -CO-HALOGENO-(C1-C3), ENTRE OTROS. TAMBIEN REFERIDA A PROCESOS PARA SU PREPARACION DONDE SON COMPUESTOS PREFERIDOS: (RS)-1-(4-BENCILOXI-FENIL)-2-OXO-PIRROLIDINA-3-CARBONITRILO; METILAMIDA DEL ACIDO (RS)-1-[4-(3-FLUORO-BENCILOXI)-FENIL]- 2-OXO-PIRROLODINA-3-CARBOXILICO Y (S)-{1-[4-(3-FLUORO-BENCILOXI)-FENIL]-2-OXO-PIRROLIDIN-3-IL}-UREA; ENTRE OTROS; Y SU USO EN LA PREPARACION Y TRATAMIENTO DE ENFERMEDADES MEDIADAS POR INHIBIDORES DE MONOAMINO OXIDASA B COMO LA DE ALZHEIMER O DEMENCIA SENIL, ENTRE OTRAS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02021319 | 2002-09-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20050077A1 true PE20050077A1 (es) | 2005-03-01 |
Family
ID=32010924
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2003000952A PE20050077A1 (es) | 2002-09-20 | 2003-09-17 | Derivados de 4-pirrolidino-fenil-bencil-eter |
| PE2003000956A PE20050078A1 (es) | 2002-09-20 | 2003-09-18 | Derivados de pirrolidona como inhibidores de maob |
| PE2003000958A PE20050079A1 (es) | 2002-09-20 | 2003-09-18 | Derivados de pirrolidona como inhibidores de maob |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2003000956A PE20050078A1 (es) | 2002-09-20 | 2003-09-18 | Derivados de pirrolidona como inhibidores de maob |
| PE2003000958A PE20050079A1 (es) | 2002-09-20 | 2003-09-18 | Derivados de pirrolidona como inhibidores de maob |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US7151111B2 (es) |
| EP (3) | EP1542971A1 (es) |
| JP (3) | JP4335142B2 (es) |
| KR (3) | KR100676014B1 (es) |
| CN (3) | CN100383118C (es) |
| AR (3) | AR041298A1 (es) |
| AT (2) | ATE459601T1 (es) |
| AU (3) | AU2003267381B2 (es) |
| BR (4) | BR0314299A (es) |
| CA (3) | CA2498785C (es) |
| CY (1) | CY1110745T1 (es) |
| DE (2) | DE60331559D1 (es) |
| DK (1) | DK1542970T3 (es) |
| ES (2) | ES2338646T3 (es) |
| GT (3) | GT200300204A (es) |
| HR (3) | HRP20050262A2 (es) |
| JO (2) | JO2604B1 (es) |
| MX (3) | MXPA05002880A (es) |
| MY (3) | MY134480A (es) |
| NO (3) | NO329754B1 (es) |
| NZ (3) | NZ538046A (es) |
| PA (3) | PA8583001A1 (es) |
| PE (3) | PE20050077A1 (es) |
| PL (3) | PL376019A1 (es) |
| PT (1) | PT1542970E (es) |
| RU (3) | RU2323209C2 (es) |
| SI (1) | SI1542970T1 (es) |
| TW (3) | TWI286132B (es) |
| UY (3) | UY27990A1 (es) |
| WO (3) | WO2004026825A1 (es) |
| ZA (3) | ZA200501137B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI286132B (en) * | 2002-09-20 | 2007-09-01 | Hoffmann La Roche | 4-pyrrolidino-phenyl-benzyl ether derivatives |
| GB0314373D0 (en) * | 2003-06-19 | 2003-07-23 | Glaxo Group Ltd | Chemical compounds |
| WO2006013049A2 (en) * | 2004-08-02 | 2006-02-09 | F.Hoffmann-La Roche Ag | Benzyloxy derivatives as maob inhibitors |
| KR100845366B1 (ko) * | 2004-08-02 | 2008-07-09 | 에프. 호프만-라 로슈 아게 | 모노아민 산화효소 ｂ 억제제로서 벤질옥시 유도체 |
| JP2008531509A (ja) | 2005-02-25 | 2008-08-14 | エフ．ホフマン−ラ ロシュ アーゲー | 医薬品成分の改良された分散性を有する錠剤 |
| MX2007011154A (es) * | 2005-03-15 | 2007-10-17 | Hoffmann La Roche | Metodo para preparar derivados de eter 4-pirrolidinofenilbencilico enantiomericamente puros. |
| US7501528B2 (en) | 2005-03-15 | 2009-03-10 | Hoffmann-La Roche Inc. | Method for preparing enantiomerically pure 4-pyrrolidino phenylbenzyl ether derivatives |
| TW200730494A (en) * | 2005-10-10 | 2007-08-16 | Glaxo Group Ltd | Novel compounds |
| TW200728258A (en) | 2005-10-10 | 2007-08-01 | Glaxo Group Ltd | Novel compounds |
| EP1943216B1 (en) * | 2005-10-10 | 2010-06-30 | Glaxo Group Limited | Prolinamide derivatives as sodium channel modulators |
| CA2706017A1 (en) * | 2007-03-30 | 2008-10-09 | Jorge R. Barrio | In vivo imaging of sulfotransferases |
| KR101220182B1 (ko) * | 2009-02-25 | 2013-01-11 | 에스케이바이오팜 주식회사 | 치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법 |
| CZ304053B6 (cs) * | 2011-08-22 | 2013-09-04 | Farmak, A. S. | Zpusob prípravy 2-[4-[(methylamino)karbonyl]-1-H-pyrazol-1-yl]adenosinu monohydrátu |
| KR102018284B1 (ko) * | 2013-02-28 | 2019-09-05 | 삼성디스플레이 주식회사 | 박막 트랜지스터 어레이 기판 및 이를 포함하는 유기 발광 표시 장치 |
| RU2661156C2 (ru) | 2013-03-14 | 2018-07-12 | Дарт Нейросайенс (Кайман) Лтд. | Замещенные нафтиридиновые и хинолиновые соединения как ингибиторы мао |
| CZ305213B6 (cs) * | 2013-04-29 | 2015-06-10 | Farmak, A. S. | Polymorf E 2-[4-[(methylamino)karbonyl]-1H-pyrazol-1-yl]adenosinu a způsob jeho přípravy |
| BR112016003288A8 (pt) | 2013-10-29 | 2020-02-04 | Hoffmann La Roche | processos para sintetizar n-[(3s)-1-[4-[(3-fluorofenil)metóxi]fenil]-5-oxo-pirrolidin-3-il]acetamida cristalina, e seu intermediário |
| US10421716B2 (en) | 2014-12-23 | 2019-09-24 | Convergence Pharmaceuticals Limited | Process for preparing alpha-carboxamide pyrrolidine derivatives |
| EP3273946A1 (en) | 2015-03-27 | 2018-01-31 | F. Hoffmann-La Roche AG | Pharmaceutical formulation comprising sembragiline |
| WO2019065794A1 (ja) | 2017-09-27 | 2019-04-04 | 国立大学法人鹿児島大学 | Ｐａｃ１受容体拮抗薬を用いた鎮痛薬 |
| CN112153968A (zh) | 2017-10-05 | 2020-12-29 | 生物基因公司 | 制备α-羧酰胺吡咯烷衍生物的工艺 |
| CN108299272B (zh) * | 2018-01-31 | 2019-10-18 | 福州大学 | 一种合成1-氯-2,2,2-三氟亚乙基取代咯酮化合物的方法 |
| SG11202008543RA (en) * | 2018-03-08 | 2020-10-29 | Sunshine Lake Pharma Co Ltd | Pyrrolidineamide derivatives and uses thereof |
| JP7501920B2 (ja) | 2019-02-27 | 2024-06-18 | 国立大学法人 鹿児島大学 | Ｐａｃ１受容体拮抗薬を用いた鎮痒薬 |
| JP7049637B1 (ja) | 2020-05-08 | 2022-04-07 | 国立大学法人 鹿児島大学 | Ｐａｃ１受容体拮抗薬を用いた抗うつ・抗不安薬 |
| CN112851561A (zh) * | 2021-01-29 | 2021-05-28 | 南京艾美斐生物医药科技有限公司 | 一种nr6a1蛋白受体抑制剂及其制备和应用 |
| WO2022268520A1 (de) | 2021-06-21 | 2022-12-29 | Bayer Aktiengesellschaft | Verwendung von substituierten pyrrolidinonen oder deren salzen zur steigerung der stresstoleranz in pflanzen. |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4348393A (en) * | 1978-06-09 | 1982-09-07 | Delalande S.A. | N-Aryl oxazolidinones, oxazolidinethiones, pyrrolidinones, pyrrolidines and thiazolidinones |
| FR2500831A1 (fr) | 1981-02-27 | 1982-09-03 | Delalande Sa | Nouvelles n-aryl-oxazolidinones et -pyrrolidinones |
| ES2087097T3 (es) | 1989-04-19 | 1996-07-16 | Otsuka Pharma Co Ltd | Derivados de acidos fenilcarboxilicos que contienen un heterociclo. |
| DE69532039T2 (de) * | 1994-08-30 | 2004-07-08 | Sankyo Co., Ltd. | Isoxazole |
| US5679715A (en) | 1995-06-07 | 1997-10-21 | Harris; Richard Y. | Method for treating multiple sclerosis |
| WO1997033572A1 (en) | 1996-03-15 | 1997-09-18 | Somerset Pharmaceuticals, Inc. | Method for preventing and treating peripheral neurophathy by administering selegiline |
| US5683404A (en) * | 1996-06-05 | 1997-11-04 | Metagen, Llc | Clamp and method for its use |
| DE19841895A1 (de) | 1998-09-11 | 2000-03-23 | Degussa | Neues Verfahren zur Herstellung von 3-Amino-2-oxo-pyrrolidinen, neue Zwischenprodukte und deren Verwendung |
| AU4181000A (en) * | 1999-04-02 | 2000-10-23 | Du Pont Pharmaceuticals Company | Novel lactam inhibitors of matrix metalloproteinases, tnf-alpha, and aggrecanase |
| AU1359801A (en) | 1999-11-05 | 2001-06-06 | Vela Pharmaceuticals Inc. | Methods and compositions for treating reward deficiency syndrome |
| WO2001058388A1 (en) * | 2000-02-10 | 2001-08-16 | Potencia Medical Ag | Urinary incontinence treatment with wireless energy supply |
| ATE296071T1 (de) * | 2000-02-14 | 2005-06-15 | Potencia Medical Ag | Penisprothese |
| TWI286132B (en) * | 2002-09-20 | 2007-09-01 | Hoffmann La Roche | 4-pyrrolidino-phenyl-benzyl ether derivatives |
| US20040267291A1 (en) * | 2003-06-27 | 2004-12-30 | Byrum Randal T. | Implantable band with non-mechanical attachment mechanism |
| US20040267292A1 (en) * | 2003-06-27 | 2004-12-30 | Byrum Randal T. | Implantable band with transverse attachment mechanism |
-
2003
- 2003-09-17 TW TW092125618A patent/TWI286132B/zh not_active IP Right Cessation
- 2003-09-17 MY MYPI20033545A patent/MY134480A/en unknown
- 2003-09-17 PA PA20038583001A patent/PA8583001A1/es unknown
- 2003-09-17 PE PE2003000952A patent/PE20050077A1/es not_active Application Discontinuation
- 2003-09-18 MY MYPI20033559A patent/MY135696A/en unknown
- 2003-09-18 RU RU2005111969/04A patent/RU2323209C2/ru not_active IP Right Cessation
- 2003-09-18 AR ARP030103384A patent/AR041298A1/es unknown
- 2003-09-18 MY MYPI20033558A patent/MY133332A/en unknown
- 2003-09-18 BR BR0314299-0A patent/BR0314299A/pt active Search and Examination
- 2003-09-18 TW TW092125735A patent/TWI337604B/zh not_active IP Right Cessation
- 2003-09-18 KR KR1020057004718A patent/KR100676014B1/ko not_active Expired - Fee Related
- 2003-09-18 UY UY27990A patent/UY27990A1/es not_active Application Discontinuation
- 2003-09-18 RU RU2005111968/04A patent/RU2336268C2/ru not_active IP Right Cessation
- 2003-09-18 GT GT200300204A patent/GT200300204A/es unknown
- 2003-09-18 AU AU2003267381A patent/AU2003267381B2/en not_active Ceased
- 2003-09-18 AR ARP030103385A patent/AR041299A1/es not_active Application Discontinuation
- 2003-09-18 NZ NZ538046A patent/NZ538046A/en not_active IP Right Cessation
- 2003-09-18 WO PCT/EP2003/010356 patent/WO2004026825A1/en not_active Ceased
- 2003-09-18 CA CA2498785A patent/CA2498785C/en not_active Expired - Fee Related
- 2003-09-18 US US10/667,087 patent/US7151111B2/en not_active Expired - Lifetime
- 2003-09-18 AR ARP030103383A patent/AR041297A1/es unknown
- 2003-09-18 MX MXPA05002880A patent/MXPA05002880A/es active IP Right Grant
- 2003-09-18 WO PCT/EP2003/010383 patent/WO2004026826A1/en not_active Ceased
- 2003-09-18 SI SI200331830T patent/SI1542970T1/sl unknown
- 2003-09-18 DE DE60331559T patent/DE60331559D1/de not_active Expired - Lifetime
- 2003-09-18 PE PE2003000956A patent/PE20050078A1/es not_active Application Discontinuation
- 2003-09-18 PL PL03376019A patent/PL376019A1/xx not_active Application Discontinuation
- 2003-09-18 AU AU2003270213A patent/AU2003270213B8/en not_active Ceased
- 2003-09-18 JP JP2004537121A patent/JP4335142B2/ja not_active Expired - Fee Related
- 2003-09-18 AT AT03748052T patent/ATE459601T1/de active
- 2003-09-18 DE DE60333202T patent/DE60333202D1/de not_active Expired - Lifetime
- 2003-09-18 CN CNB038219522A patent/CN100383118C/zh not_active Expired - Fee Related
- 2003-09-18 AT AT03750564T patent/ATE472530T1/de active
- 2003-09-18 MX MXPA05002878A patent/MXPA05002878A/es active IP Right Grant
- 2003-09-18 PL PL376021A patent/PL216030B1/pl unknown
- 2003-09-18 AU AU2003273901A patent/AU2003273901B2/en not_active Ceased
- 2003-09-18 WO PCT/EP2003/010384 patent/WO2004026827A1/en not_active Ceased
- 2003-09-18 EP EP03757866A patent/EP1542971A1/en not_active Withdrawn
- 2003-09-18 MX MXPA05002881A patent/MXPA05002881A/es active IP Right Grant
- 2003-09-18 PA PA20038583601A patent/PA8583601A1/es unknown
- 2003-09-18 BR BR0314314-7A patent/BR0314314A/pt not_active IP Right Cessation
- 2003-09-18 RU RU2005111974/04A patent/RU2336267C2/ru not_active IP Right Cessation
- 2003-09-18 KR KR1020057004699A patent/KR100681586B1/ko not_active Expired - Fee Related
- 2003-09-18 PE PE2003000958A patent/PE20050079A1/es active IP Right Grant
- 2003-09-18 JO JO2003115A patent/JO2604B1/en active
- 2003-09-18 PA PA20038583501A patent/PA8583501A1/es unknown
- 2003-09-18 GT GT200300205A patent/GT200300205A/es unknown
- 2003-09-18 CA CA2496756A patent/CA2496756C/en not_active Expired - Fee Related
- 2003-09-18 CN CNB038217678A patent/CN100400509C/zh not_active Expired - Fee Related
- 2003-09-18 KR KR1020057004683A patent/KR100676015B1/ko not_active Expired - Fee Related
- 2003-09-18 TW TW092125746A patent/TWI331994B/zh not_active IP Right Cessation
- 2003-09-18 HR HR20050262A patent/HRP20050262A2/xx not_active Application Discontinuation
- 2003-09-18 UY UY27991A patent/UY27991A1/es not_active Application Discontinuation
- 2003-09-18 US US10/667,088 patent/US7037935B2/en not_active Expired - Fee Related
- 2003-09-18 HR HR20050261A patent/HRP20050261A2/hr not_active Application Discontinuation
- 2003-09-18 PT PT03750564T patent/PT1542970E/pt unknown
- 2003-09-18 EP EP03748052A patent/EP1542969B1/en not_active Expired - Lifetime
- 2003-09-18 JP JP2004537120A patent/JP4335141B2/ja not_active Expired - Fee Related
- 2003-09-18 PL PL03376018A patent/PL376018A1/xx not_active Application Discontinuation
- 2003-09-18 JP JP2004537119A patent/JP4335140B2/ja not_active Expired - Fee Related
- 2003-09-18 ES ES03748052T patent/ES2338646T3/es not_active Expired - Lifetime
- 2003-09-18 HR HRP20050263AA patent/HRP20050263B1/hr not_active IP Right Cessation
- 2003-09-18 ES ES03750564T patent/ES2344557T3/es not_active Expired - Lifetime
- 2003-09-18 DK DK03750564.1T patent/DK1542970T3/da active
- 2003-09-18 JO JO2003116A patent/JO2605B1/en active
- 2003-09-18 GT GT200300206A patent/GT200300206A/es unknown
- 2003-09-18 NZ NZ538049A patent/NZ538049A/en unknown
- 2003-09-18 BR BR0314631-6A patent/BR0314631A/pt not_active IP Right Cessation
- 2003-09-18 NZ NZ538048A patent/NZ538048A/en not_active IP Right Cessation
- 2003-09-18 BR BRPI0314631-6A patent/BRPI0314631B1/pt unknown
- 2003-09-18 EP EP03750564A patent/EP1542970B1/en not_active Expired - Lifetime
- 2003-09-18 CA CA002498335A patent/CA2498335A1/en not_active Abandoned
- 2003-09-18 US US10/666,594 patent/US7235581B2/en not_active Expired - Fee Related
- 2003-09-18 CN CNB038212560A patent/CN100503562C/zh not_active Expired - Fee Related
- 2003-09-19 UY UY27993A patent/UY27993A1/es not_active Application Discontinuation
-
2005
- 2005-02-08 ZA ZA200501137A patent/ZA200501137B/xx unknown
- 2005-02-08 NO NO20050652A patent/NO329754B1/no not_active IP Right Cessation
- 2005-02-08 NO NO20050665A patent/NO330012B1/no not_active IP Right Cessation
- 2005-02-09 NO NO20050701A patent/NO20050701L/no not_active Application Discontinuation
- 2005-02-14 ZA ZA200501311A patent/ZA200501311B/en unknown
- 2005-02-22 ZA ZA200501557A patent/ZA200501557B/xx unknown
-
2006
- 2006-01-05 US US11/325,747 patent/US7122562B2/en not_active Expired - Fee Related
-
2010
- 2010-08-20 CY CY20101100770T patent/CY1110745T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20050077A1 (es) | Derivados de 4-pirrolidino-fenil-bencil-eter | |
| NO20063748L (no) | Kinolinderivater og anvendelse derav som mykobakterielle inhibitorer | |
| ATE348814T1 (de) | Verfahren zur herstellung von chinolinderivaten | |
| PE20090837A1 (es) | Nuevos compuestos quimicos | |
| CY1109227T1 (el) | Παραγωγα της 5-φαινυλο-4-μεθυλο-θειαζολ-2-υλ-αμινης ως αναστολεις των ενζυμων κινασης της φωσφατιδυλινοσιτολης 3 (p13) για την θεραπεια των φλεγμονωδων ασθενειων των αεραγωγων | |
| NO20052755D0 (no) | Krystallmodifikasjon av et N-fenyl-2-pyrimidinaminderivat, fremgangsmate for dens fremstilling og dens anvendelse. | |
| ATE368656T1 (de) | Piperidinderivate zur verwendung bei der behandlung von durch chemokins vermittelten leiden | |
| ATE381552T1 (de) | Derivate von 1-piperazin- und 1- homopiperazincarboxylaten, verfahren zu deren herstellung und deren verwendung als inhibitoren des faah-enzyms | |
| PE20040667A1 (es) | Derivados de cinamida | |
| PE20060298A1 (es) | Derivados de acido carboxilico de bencimidazolona | |
| AR035111A1 (es) | Procedimiento para preparar un compuesto de pirimidinona | |
| DE60315664D1 (de) | Verfahren zur herstellung von 5-(1,3-oxazol-2-yl)benzoesäurederivaten | |
| PE20040520A1 (es) | Derivados de n-acilamino bencil eter | |
| PE20040594A1 (es) | Derivados de isoquinolina | |
| PE20050587A1 (es) | Derivados de diazindol-dicarbonilo-piperazinilo como agentes antivirales | |
| ATE340791T1 (de) | Herstellung und verwendung von 2-substituierten 5-oxo-3-pyrazolidincarboxylaten | |
| ATE518835T1 (de) | Kristallform einer chinolinverbindung und verfahren zu deren herstellung | |
| EA200701470A1 (ru) | Способы получения производных 4-(фенокси-5-метилпиримидин-4-илокси)пиперидин-1-карбоновой кислоты и родственных соединений | |
| ZA200704913B (en) | 3-[2-(3-acylamino-2-oxo-2H-pyridin-1-YL)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors | |
| DE60310609D1 (de) | Verfahren zur herstellung von 2-aminomethylpyridin-derivaten | |
| NO20062936L (no) | Fremgangsmate for fremstilling av N-alkyl-2(hydroksy-4-benzoyl)-3-benzofuraner og dets mellomprodukter derav | |
| NO20070972L (no) | Benzyloksyderivater som MAOB-inhibitorer | |
| ATE546432T1 (de) | Verfahren zur herstellung von 2- aminomethylpyridin-derivate | |
| WO2005040129A3 (en) | Ccr3 receptor antagonists | |
| DE602004007150D1 (de) | 1,3-disubstituierte azetidinderivate zur verwendung als antagonisten des ccr-3-rezeptors bei der behandlung von entzündlichen und allergischen krankheiten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |